NeurologyLive® Top Expert Interviews: June 2022
Expert clinicians offer their insight on the sleep disorder landscape, the state of mental health in pediatric migraine, an inaugural movement disorders congress, a novel stroke rehabilitation tool, and psychedelics in cluster headache.
The NeurologyLive® team has been as busy as always bringing you the latest clinical news and research updates in neurology over the last month, including conducting several interviews with experts across a number of different and varying topics.
Among these included conversations on the impact of sodium oxybate formulations on the sleep disorder landscape with Richard Bogan, MD, FCCP, FAASM; the state of mental health among pediatric patients with migraine with Serena L. Orr, MD, MSc; the highlights of the inaugural Advanced Therapeutics in Movement and Related Disorders Congress with Jean Hubble, MD; the potential of a novel stroke rehabilitation tool with Heidi Schambra, MD; and the assessment of psychedelics in cluster headache with Byran Roth, MD, PhD.
Click through the slides to see and read more from each expert’s exclusive conversation with NeurologyLive® in June 2022.
Click the image to watch this video, or the sides of the image to see the next video.
WATCH TIME: 3 minutes
Expanding Knowledge About Advantages of Low-Sodium Oxybates: Richard Bogan, MD, FCCP, FAASM
"I take to mind the fact that the FDA said this is a clinically superior drug. It’s a safer drug, it has lower sodium, and it’s still oxybate, the same moiety. Now, we’ve got clinical experience with the drug in terms of transitioning patients from Xyrem to Xywav, the lower sodium moiety. For most people, it’s gram-for-gram and fairly easy for patients to understand."
In July 2020, the FDA approved JZP-258 (Xywav; Jazz Pharmaceutical), an oral solution of calcium, magnesium, potassium, and sodium oxybates, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age or older with narcolepsy. A little more than a year later, the FDA approved an expanded indication of the drug to include patients with idiopathic hypersomnia, becoming the first treatment approved for this indication.
Since its original approval, the therapeutic has been featured in numerous analyses further demonstrating its efficacy and safety in both populations, including some presented at this year’s 2022 SLEEP Annual Meeting, June 4-8, in Charlotte, North Carolina. Richard Bogan, MD, FCCP, FAASM, was the lead investigator for the phase 3 study that led to JZP-258’s approval in narcolepsy. He sat down with NeurologyLive® at the meeting to discuss the advantages of low-sodium oxybate, and the improved overall knowledge of the drug since it first hit the market.
To hear more insight from experts in the clinical care of patients and leading researchers in neurology, check out more of NeurologyLive®'s videos.
